Abstract: In order to stabilize solutions of human albumin for therapeutic use for the purpose of their treatment by heat in a container, in particular in the final container, there is added, in addition to the usual stabilizing formula, a surfactant agent selected from among Tween 80, Tween 20, Pluronic F68, laurate of polyethylene glycol 600 or any other equivalent agent.

Abstract: A benzoyl urea compound-albumin complex comprising a benzoyl urea compound of the formula: ##STR1## wherein X is a halogen atom or a nitro group, Y is a hydrogen atom, a halogen atom, a nitro group or a trifluoromethyl group, Z.sub.1 is a halogen atom or a trifluoromethyl group, Z.sub.2 is a hydrogen atom or a halogen atom and A is CH or a nitrogen atom, and albumin.

Abstract: A method for purifying hemoglobin, mixed with other proteins is described, wherein the mixture is contacted with an ion exchange matrix so that the hemoglobin is adsorbed to it. The matrix is washed to remove unadsorbed components, and the hemoglobin is then selectively eluted using a ligand which specifically binds the hemoglobin causing it to desorb from the matrix. The method can also be used to effect reduction of methemoglobin to hemoglobin on an ion exchange matrix followed by selective elution to achieve purification. The method can also be used to purify methemoglobin.

Abstract: A method for the prophylaxis or direct treatment of inflammation in a mammal which comprises administering an effective amount of alpha 1-antichymotrypsin, its salts or derivatives, and compositions thereof.

Abstract: Analogs of CRF are disclosed that can be administered to achieve a substantial elevation of ACTH, .beta.-endorphin, .beta.-lipotropin, other products of the pro-opiomelanocortin gene and corticosterone levels and/or a lowering of blood pressure over an extended period of time. One analog which has been found to be particularly preferred is: [His.sup.20, Nle.sup.21, Leu.sup.38 ]-rCRF. In the analogs, one or more of the first five N-terminals residues may be deleted or may be substituted by a peptide up to 10 amino acids long and/or by an acylating agent containing up to 7 carbon atoms. A number of other substitutions may also be made throughout the chain. These analogs or pharmaceutically or veterinarily acceptable salts thereof, dispersed in a pharmaceutically or veterinarily acceptable liquid or solid carrier, can be administered to mammels, including humans. These analogs may also be used as stimulants to elevate mood and improve memory and learning.

Abstract: A method of potentiating immunotoxin action in an immunotoxin/target-cell stem in which Brefeldin A is utilized as an immunopotentiator. The Brefeldin A enhances the immunotoxin pathway while blocking or inhibiting the nonspecific pathway, thus being particularly useful in conjunction with immunotoxins made from holotoxins. The Brefeldin A is effective in small, nontoxic concentrations and therefore may be utilized with either in vivo or in vitro systems.

Abstract: Methods for the treatment of allergic reactions are provided, wherein a pharmaceutically effective dose of gamma interferon is administered to a patient within a predetermined temporal period prior to or following exposure to an allergen.

Abstract: The present invention relates to novel "pseudo" nonapeptide and decapeptide derivatives of LHRH. More particularly the present invention relates to derivatives of LHRH wherein the nitrogen atom of at least one of the amide bonds has been alkylated.

Abstract: The subject of the invention is a procedure for the preparation of water-soluble macromolecular conjugates of hemoglobin, characterized in that:in the first step, Z sites are bound to a polymer P, the Z sites containing, on the one hand, at least one negative charge borne for example by sulfate groups and intended to lead to the formation of an ionic linkage with hemoglobin, and containing, on the other hand, at least one carboxylic group for example intended to lead to the formation of a covalent linkage with hemoglobin,then in the second step, the polymer P containing the Z site(s) is made to react with hemoglobin in the oxygenated form in order to form, on the one hand, at least one ionic linkage between at least one of the Z sites borne by the polymer and hemoglobin and, on the other hand, at least one covalent linkage between the same Z site mentioned above borne by the polymer and hemoglobin.

Abstract: A method for the solubilization and naturation of somatotropin from refractile bodies produced by r-DNA technology wherein the refractile bodies are dissolved in an aqueous solution comprising a chaotropic agent such as urea or guanidine hydrochloride and a soluble organic alcohol such as isopropanol or benzyl alcohol. The solubilized protein is exposed to mild oxidation for a time sufficient to allow the protein to form disulfide bonds and refold to its native conformation. The presence of the alcohol suppresses the formation of somatotropin dimers and aggregates and results in higher yields of the desirable monomeric form of the protein.

Abstract: A method of predisposing a mammal to accelerated tissue repair is provided. This method comprises systemically administering to the mammal, prior to its exposure to tissue damage, an effective amount of TGF-.beta.. Preferably, the TGF-.beta. is administered no more than about 24 hours prior to exposure to tissue damage.

Abstract: A method of causing an animal to gain weight by administering that animal a T-cell growth factor comprising Interleukin-2 (IL-2) in an amount effective to cause that animal to increase in weight is disclosed. A method of treating birds by administering birds in ovo avian IL-2 is also disclosed. The method is preferably carried out on chicken with 30K chicken IL-2 on about the eighteenth day of incubation. The method may be employed to increase the weight of treated birds after hatch. A vaccine may optionally be administered concurrently with the avian IL-2.

Abstract: The present invention relates to methods for improving cheese production by utilizing plasmin-regulating agents to maintain milk plasmin concentration in milk used to make cheese at that found at early lactation or at less than 0.2 mg/l milk.

Abstract: The subject invention concerns the use of a novel and useful bioinsecticide against the lesser mealworm (Alphitobius diaperinus). The lesser mealworm is a devastating pest in the poultry industry. The bioinsecticide of the subject invention is a novel B. thuringiensis microbe referred to as B.t. PS122D3, or mutants thereof. The spores or toxin crystals of this microbe are useful to control the lesser mealworm in various environments.

Abstract: A composition comprising arginine enriched whey protein can be used in the formulation of a variety of simulated food products to provide a substantially fat free, calorie controlled diet which delivers high levels of protein having a hypocholesterolemic amino acid profile.

Abstract: Insulin-like growth factor I (IGF I) and pharmaceutical compositions comprising IGF I are useful in improving glomerular filtration and renal plasma flow and can be used for the treatment of patients suffering from renal diseases and for the preparation of therapeutic combinations for treatment of renal diseases.

Abstract: This invention relates to collagen compositions and methods of preparing such compositions. This invention also relates to a novel source of collagen, the common digital extensor tendon.

Abstract: Synthesis and use of novel oligopeptides are described, many of which peptides contain one or several unnatural amino acids. These short linear peptide derivatives are characterized by the presence of a free sulfhydryl function. These compounds have a high affinity for the Atrial Natriuretic Peptide (ANP) receptor coupled to particulate guanylate cyclase. Such peptides are full agonists at the ANP receptor as demonstrated by the ability of the peptides to stimulate the production of cGMP and to relax smooth muscles in vitro. In accord with these observations, the compounds of the invention lower blood pressure in mammals. Preferred peptides are the following:Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-GlyNH.sub.2 ; D-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-GlyNH.sub.2 ; L-Pen-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-GlyNH.sub.2 ; and Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-IleNH.sub.2.

Abstract: Various specific human SP-18 and human SP-5 derived peptides have alveolar surfactant protein (ASP) activity. These peptides are prepared using synthetic methods or by recombinant techniques. The peptides of the invention include surfactant proteins having serine replacements for the cysteines.

Abstract: Recombinant hepatitis B virus surface proteins produced in recombinant host cells are rapidly and efficiently purified from either cell extracts in a high pH buffer, or from heated whole cells at neutral pH. The host cell extracts or whole cells are heat treated, cooled and in the case of high pH extract, the pH is reduced. The surface proteins are then absorbed onto wide pore silica followed by elution and concentration. This method eliminates the requisite introduction of protease inhibitors, stabilizes the surface protein and improves product yield.